Navigation Links
Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
Date:9/23/2008

FREDERICK, Md., Sept. 23 /PRNewswire/ -- Arisyn Therapeutics Inc. (Arisyn) announced today day that it has successfully acquired from UAF Technologies and Research, L.L.C. (UTR) a series of highly novel small molecule inhibitors with a well-defined preclinical efficacy spectrum against a variety of infectious organisms and cancer. Under the terms of the assignment, Arisyn will assume the intellectual property portfolio. In return, UTR will receive a cash assignment fee, cash payments on the achievement of certain defined milestones and royalties on future sales of derivative drugs.

The assets involved in the transaction include molecules originally developed by The Proctor and Gamble Company, which were donated in 2003 to UTR for research at the University of Arizona. The therapeutic agents which constitute the portfolio target the replication of the human immunodeficiency virus (HIV), human T-cell leukemia virus (HTLV-1), hepatitis C virus (HCV), influenza virus, herpes viruses, and also include broad based inhibitors of cancer. Lead compounds from the series for HIV and cancer have already been tested in Phase 1 human clinical trials, while a lead inhibitor of HCV has progressed to the submission of an IND application with the FDA. The compounds inhibit virus replication by a highly unique mechanism of action involving inhibition of viral RNA transcription and have been found to be safe in extensive toxicological evaluations.

"These novel inhibitors form the basis of a new strategy to treat infectious disease by targeting a critical viral replication pathway within the infected cell and turning off the production of progeny infectious virus. The therapeutic agents should be highly effective additions to the combination therapy regimens currently used to treat infectious disease and of immense benefit to the millions of individuals chronically infected with organisms such as HIV and HCV," noted Robert W. Buckheit, Jr., Ph.D., Director of Research and Development for Arisyn. "The compounds have proven efficacy and safety in preclinical studies and have shown significant promise to progress to Phase 1 human clinical trials for the treatment of HIV and cancer."

The continued preclinical and clinical development of the compound portfolio will be performed by ImQuest BioSciences, a Contract Research Organization located in Frederick, MD specializing in the development of drugs for the treatment of infectious disease and cancer. ImQuest will perform necessary preclinical and clinical studies and manage the evaluation of Arisyn's compounds in human clinical trials, as well as assist Arisyn with the discovery of next generation inhibitors of the novel therapeutic targets.

Bo Statham, UTR Manager, said he is very pleased that this promising technology has been assigned to Arisyn, a company that will focus exclusively on the development of these drugs.

About UTR

UTR is a limited liability company that was established to benefit the University of Arizona in the development of patents and other technology and to license or otherwise transfer such intellectual property to third parties.

About Arisyn Therapeutics Inc.

Arisyn Therapeutics Inc. is a privately held biotechnology company focused on the clinical development of small molecule therapeutics for infectious diseases and cancer. Arisyn's strategy is to develop novel inhibitors with unique mechanisms of action for chronic diseases without effective therapeutic options such as HIV, hepatitis, and cancer. Arisyn Therapeutics Inc. is based in Frederick, Maryland and is on the web at http://www.Arisyn.com.

About ImQuest BioSciences, Inc.

ImQuest BioSciences, a privately held U.S. company located in Frederick, Maryland is a leading provider of anti-infective therapeutic and microbicide development and anti-cancer services to the biotechnology and pharmaceutical industry. ImQuest has broad based capabilities to assist companies with the discovery and preclinical development of new therapeutics, vaccines and preventatives, as well as the management of IND-directed programs for the evaluation of active products in human clinical trials. ImQuest is on the web at http://www.imquest.com.

For further information regarding this press release, please contact:

Robert W. Buckheit, Jr., Ph.D.

Director of Research and Development

Arisyn Therapeutics Inc.

(301) 644-3921

rbuckheit@arisyn.com

Bo Statham

bostatham@comcast.net

(520) 519-9300


'/>"/>
SOURCE Arisyn Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... fully-certified hygienic SWB805 MultiMountTM weigh modules. These weigh modules are designed according ... National Sanitation Foundation (NSF). , As fully integrated weighing solutions, SWB805 MultiMount ...
(Date:3/27/2017)... ... 27, 2017 , ... IsoPlexis Corporation (IsoPlexis), a venture capital-funded ... more through a single-cell precision engineering platform, today announced it has received an ... the laboratory of Dr. James Heath at the California Institute of Technology, a ...
(Date:3/27/2017)... March 27, 2017  Perthera,s Chief Bioinformatics Officer and ... Subha Madhavan , Ph.D., will be speaking at the ... On Monday, March 27, 2017, she will be speaking ... Usable for Research and Care" (from 10:30 a.m. – ... she will be a participant in the "Making Precision ...
(Date:3/27/2017)... , March 27, 2017 DarioHealth Corp. (NASDAQ: ... health and big data solutions, today announced that it ... coverage option for U.S. consumers who want to have ... DarioHealth has signed strategic alliance agreements with partners across ... coverage benefits, and if approved, will supply and bill ...
Breaking Biology Technology:
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel visited the ... the DERMALOG stand together with the Japanese Prime Minster Shinzo Abe. ... largest German biometrics company the two government leaders could see the three ... as DERMALOG´s multi-biometrics system.   Continue Reading ... ...
(Date:3/9/2017)... SAN FRANCISCO and MOUNTAIN VIEW, ... Zipongo , "Eating Well Made Simple," and 23andMe ... to help guide better food choices.  Zipongo can now ... only their food preferences, health goals and biometrics, but ... to certain food choices. Zipongo,s personalized food ...
Breaking Biology News(10 mins):